Clinical Trial Update: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation [Phase 2]

View source ↗

Summary

A Phase II trial of TQC3721 suspension for inhalation in chronic obstructive pulmonary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721 Suspension for Inhalation (TQC3721)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: TERMINATED